Visceral Adiposity Replaces Age as Primary Driver of Low Testosterone
A Los Angeles internal medicine specialist treated a patient in his early 50s who had spent a decade on testosterone replacement therapy before learning his low hormone levels stemmed from excess adiposity rather than aging, Medscape reported.
“It took a lot of time for me to gain his trust,” Wayne T. Ho said of the patient who initially balked at abandoning his prescription, according to Medscape.
Dr. Ho eventually prescribed a GLP-1 alongside diet and lifestyle changes. The patient dropped roughly 60 pounds, his testosterone rebounded to normal levels, and he successfully stopped the replacement therapy.
Data Links Body Fat to Hormone Variability
Researchers analyzing data from nearly 5,000 men between the ages of 20 and 59 found that body fat acts as the dominant determinant of circulating testosterone. Adam W. Potter and Karl E. Friedl of the US Army Research Institute of Environmental Medicine in Natick, Massachusetts, published findings showing that biochemically low testosterone consistently tracked with greater adiposity across all age brackets.
The study evaluated data from the National Health and Nutrition Examination Survey spanning 2011 through 2016. Age alone explained just 2.5% of the variation in circulating testosterone levels. By contrast, DEXA-derived body fat, visceral adipose tissue, and waist circumference accounted for 18% to 20% of that same variability.
Visceral adiposity displayed a stronger inverse association with testosterone than total body adiposity. Men aged 30 to 39 with low testosterone registered a mean total percent body fat of 30.3%, compared to 26.4% for peers with normal testosterone levels.
Clinical Guidelines and Regulatory Scrutiny
The findings arrive amid heightened regulatory and professional attention directed at testosterone therapies. The Food and Drug Administration has requested updates to product labels, while the Department of Defense is screening military personnel aged 30 and older for deficiency.
The Endocrine Society issued a statement emphasizing accurate hypogonadism diagnoses. Richard Auchus, a professor of pharmacology and internal medicine at the University of Michigan Health, advises primary care providers to investigate secondary causes like obesity, narcotics, and sleep apnea before prescribing testosterone replacement therapy.
“People with obesity have a chronic illness and that secondarily impairs their testosterone production,” Auchus said, according to Medscape.
Endocrinologists Support Lifestyle Interventions
Christopher A. Muir, an endocrinologist at Concord Hospital in Sydney, Australia, reviewed the research for Medscape and noted it aligns with his own clinical observations. Muir recently described a patient whose weight dropped from 260 pounds to 207 pounds following a 12-month lifestyle and GLP-1 program, which lifted his testosterone from 147 ng/dL to 467 ng/dL.
While real-world data points to obesity driving testosterone reduction, Muir cautioned that some obese patients do experience genuine testosterone deficiency. He recommends running additional blood tests, including follicle-stimulating hormone and luteinizing hormone assessments, to confirm diagnoses.
Fat distribution reshapes testosterone levels
Does aging cause low testosterone?
Researchers found that age accounts for only 2.5% of the variation in circulating testosterone levels. Excess body fat and visceral adiposity explain up to 20% of that variability across adult age groups.
How does visceral fat impact testosterone?
Excess adipose tissue alters hormone regulation by increasing the aromatization of testosterone to estradiol and driving insulin resistance that reduces hepatic sex hormone-binding globulin synthesis.
Can weight loss reverse low testosterone?
Clinical case reports and specialist observations show that weight loss achieved through diet, lifestyle modifications, and GLP-1 medications can restore testosterone to normal ranges without hormone replacement therapy.
What screening guidelines apply to testosterone deficiency?
The Endocrine Society released guidance citing insufficient evidence to support population-wide screening for hypogonadism in asymptomatic men.
Worth a look